Redeye leaves its initial comments on Xbrane's Q1 report, which came in softer than we had pencilled...
Redeye comments on the news from Google, where it is developing a new scam detection feature.
Marimekko’s Q1 figures exceeded our estimates driven by the timing of non-recurring wholesale promot...
Redeye sees a Q1 report from Genovis largely aligning with our estimates with minor deviation on the...
Somewhat surprising, the QoQ reduction in order backlog from SEK 23m in Q4’23 to SEK 15m in Q1’24 wa...
Redeye comments on yesterday’s news about Apple launching Eye tracking.
Redeye updates its estimates following Surgical Science’s Q1 2024 report, which came in considerably...
Redeye updates its estimates following Sozap’s Q1 report.
Q1: sales EUR 42m, +9% y-o-y, order intake EUR 40m, -5% y-o-y We lower '24e-'26e sales and order int...
Arctic Blue Beverages har publicerat bolagets delårsrapport för det första kvartalet år 2024.
En investering i MTI Investment SE (”MTI” eller ”Bolaget”) ger exponering mot bolag i en stark tillv...
As announced already in February, capacity utilization and turnover in Q1 were weighed down by the p...
Redeye returns with a more in-depth take on the Q1 report.
I samband med Eisais rapport annonserades att företaget räknar med en försäljning av Leqembi på JPY5...
Redeye provides its initial take on Surgical Science’s Q1 2024 report, which featured contrasting de...
Redeye comments on Thunderful Group’s Q1'24 report, which was weak and came in line with preliminary...
Marimekko’s Q1 results came in stronger than expected driven partly by the timing of non-recurring w...
Redeye comments on Sozap’s Q1 results, which revealed sales roughly in line with expectations, while...
Redeye updates its view on Acarix following its Q1 report.
Redeye provides an research update following Starbreeze Q1-report; Some positive comments from manag...
